Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of autoantibodies directed against nuclear self-antigens and circulating immune complexes. This results in damages to various organs or systems, including skin, joints, kidneys and the central nervous system. Clinical manifestations of SLE could be diverse, including glomerulonephritis, dermatitis, thrombosis, vasculitis, seizures and arthritis. The complicated pathogenesis and varied clinical symptoms of SLE pose great challenges in the diagnosis and monitoring of this disease. Unfortunately, the etiological factors and pathogenesis of SLE are still not completely understood. It is noteworthy that recent advances in our understanding of the biological omics and emerging technologies have been providing new tools in the analyses of SLE, such as genomics, epigenomics, transcriptomics, proteomics, metabolomics and so on. In this article, we summarize our current knowledge in this field for a better understanding of the pathogenesis, diagnosis and treatment for SLE.
INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune systemic disease, and 90% of the cases of SLE occur in women. It is characterized by the presence of large quantities of autoantibodies to components of the cell nucleus. These autoantibodies and some self-reactive T cells contribute directly to the pathologic changes in SLE. The generation of autoantibodies is the result of a cascade of immune dysregulation, including inappropriate regulation of hyperreactive B and T cells, loss of immune tolerance and defective clearance of apoptotic cells and immune complexes in the presence of an appropriate genetic predisposition. The role of genetic variation has been extensively investigated in the lupus, revealing polymorphisms throughout the genome correlated with disease. Although studies investigating common genetic variants in SIE have revealed a number of susceptibility loci, not all carriers develop clinical disease, and patients with the same or similar alleles might present with different disease course. As a complex human disease, it may broadly reside in epigenetic mechanisms. Epigenomics describes changes in gene expression not linked to alterations in the underlying genomic sequence, whereas environmental factors, such as medications, hormones, stress, infections, cigarette exposure, UV exposure and toxicants, can modify epigenetic marks, influencing disease onset and progression. [1] [2] [3] [4] Moreover, transcription factors (TFs) play a central role in regulating gene expression and transcription. Indeed, there is growing evidence showing that there is a significant correlation between SLE and TFs. In addition, RNA editing and alternative splicing can therefore correct, extend or diversify the information encoded within the corresponding genomic sequence, and translational control is an important regulatory mechanism for growth-related genes and cytokine expression. Protein is the executor of physiological function. Posttranslational modifications (PTMs) alter many aspects of protein chemistry, including primary and tertiary structure, biological (and/or enzymatic) functions and proteolytic degradation that may be critical in generating immunogenic or tolerogenic self-peptides, which also play an important role in the initiation and propagation of SLE.
In summary, the pathogenesis of SLE probably involves multiple factors, and each of these factors acts both independently and concurrently, and may differ between individuals. Thus, a large body of work has been done, but the mechanisms of SLE pathogenesis are still not completely understood and the cause of the diversity of symptoms is not full clear. Until now, renal biopsy remains the 'gold standard' for assessing disease severity, but multiple biopsies to gauge treatment efficacy are not feasible because of their invasive nature. Development of biomarkers for a deeper understanding of SLE pathogenesis and improving diagnosis, prognosis, and treatment is still one of the main goals and challenges in SLE research. Alternative biomarker discovery approaches include proteomics, metabolomics and so on that may help to find new biomarkers that can be used to more reliably and securely confirm SLE or monitor their progression with high sensitivity and specificity. In this paper, our goal is to provide a brief overview of current research of SLE and to introduce some of the key discussion points in terms of understanding of lupus pathogenesis and providing new targets for therapy.
GENOME RESEARCH OF SLE
During the past decades, linkage studies and candidate gene studies have assessed many genes for potential roles in predisposing to SLE. Until now, the number of confirmed genes predisposing to SLE is over 30 (Table 1) , and many candidate genes have been identified based on their location or possible pathogenic roles. Specific characteristics of the human leukocyte antigen (HLA) region, as well as complement factor deficiencies, may facilitate nuclear antigen presentation, thereby triggering autoantibody production. The genetic polymorphism of cytokines may conduce to deregulate lymphocyte activity. Furthermore, the polymorphism of the Fc receptors of immunoglobulins may affect immune complex clearance, thereby promoting tissue damage.
Major histocompatibility complex The extended major histocompatibility complex is a gene-dense, transcriptionally active, 7.6-Mb interval on chromosome 6p21.3. It comprises the classical HLA class I (HLA-A, -B and -C) and class II regions (HLA-DR, -DQ and -DP) that encode the genes involved in antigen presentation. This region is highly polymorphic and, not surprisingly, has been associated with most of the autoimmune, inflammatory and infectious diseases.
HLA class II. Many studies, the earliest of which were done more than 20 years ago, have shown that SLE is associated with HLA class II haplotypes involving the HLA-DRB1 and HLA-DQB1 loci; in particular, haplotypes bearing the DRB1*1501/DQB1*0602 (DR2) and DRB1*0301/DQB1*0201 (DR3) alleles have been associated with SLE in Caucasian populations, and studies suggest that these alleles confer an overall two-to threefold increased risk for SLE. 5 Class II HLA specificities seem associated mainly with specific autoantibody profiles. In general, compared with Caucasians, the HLA association in non-Caucasian populations is less well established.
HLA class III and the complement system. In the class III gene, mutS homolog 5 (MSH5) gene has been associated with SLE, and the strongest association was confirmed in a genome-wide association study by Harley et al. 6 Superkiller viralicidic activity 2-like (SKIV2L), is another class III gene for potential roles in SLE, and a study of 314 trios from the United Kingdom implicated this locus independent of class II variants. 7 The integrin a M (ITGAM) gene has also been associated with SLE in a number of studies. 6, 8 Additionally, it is notable that the strongest single genetic risk factors of SLE are complement defects. For instance, 90% of homozygous C1q-deficient individuals develop SLE.
9
C1q participates in the clearance of apoptotic cells, and thus has a role in the maintenance of immune tolerance. A hierarchy of susceptibility among the absence of classical complement component (C1q4C44C2, in decreasing order of risk for SLE susceptibility) has been suggested. 10 The C4 fraction of complement is encoded by two class II genes, C4A and C4B. Complete C4 deficiency is associated with a 70% risk of SLE development. Lower copy number of C4 is a risk factor for SLE, and higher gene copy number of C4 is a protective factor against SLE disease susceptibility.
11
IgG Fc receptor (FCGR) Fc g-receptors (FcgRs) are members of the immunoglobulin superfamily that recognize and bind the constant (Fc) portion of specific monomeric immunoglobulin G (IgG) and IgG-containing 13 This allelic difference alters recognition of ligand. The FcgRIIA-H131 (histidine residue at position 131) allele is able to bind IgG2 effectively, whereas the R131 (arginine residue at position 131) binds less efficiently to IgG2 and might delay clearance of IgG2-containing immune complexes. 12 Moreover, a single-nucleotide polymorphism (SNP) corresponding to isoleucine (I) to threonine (T) at the FcgRIIb residue 232 (also known as I/T 187 excluding the signal peptide) in the transmembrane domain that may alter the B-cell receptor signaling has been associated with SLE in the Chinese, Japanese and Thai populations, [14] [15] [16] but not in the Blacks and Whites in the United States and the Swedish Whites. 17, 18 Therefore, the FCGR2B I/T 232 may be a risk factor for SLE in Asians but not in other studied populations. In 2004, a study by Su et al. 19 showed a promoter haplotype that alters FcgRIIb promoter activity. The less frequent promoter haplotype ( À 386C À 120A) showed increased promoter activity and drove higher receptor expression in both transfected cell lines and cells ex vivo from genotyped donors than the more frequent haplotype ( À 386G À 120T). 19, 20 The less frequent and more active promoter haplotype was associated with SLE in a Caucasian population with an odds ratio of 1.6. FcgRIIIs. FcgRIIIa (CD16) is expressed on cell surfaces of natural killer cells, monocytes and macrophages, and it binds to both IgG1 and IgG3 subclasses. A T-G polymorphism results in phenylalanine (F)-valine (V) at amino-acid 176.
12 Individuals homozygous for F-F bind IgG1 and IgG3 less efficiently than those with V-V genotypes, suggesting less efficient clearance of IgG1-or IgG3-containing immune complexes. 12 A recent meta-analysis of 41000 subjects in each of the three categories (lupus nephritis (LN), SLE without renal involvement and non-SLE controls) has concluded that the 176 F allele confers a 1.2-fold increased risk for developing LN in patients of European, African and Asian descent but not for SLE susceptibility per se in the absence of nephritis. 21 Furthermore, three different allotypic variants of FCGR3B, NA1, NA2 and SH, have been identified through serological studies. The six SNP differences underlying these three serologic allotypes include five nonsynonymous SNPs and one synonymous SNP. The five aminoacid changes are all in the first extracellular domain of FcgRIIIb. Among these, the amino-acid 65 change results in a loss of a glycosylation site in the NA2 allele. 22 The NA2/NA2 variant has been shown to confer reduced phagocytic capacity of neutrophils as compared with the NA1/NA1 genotype and is possibly associated with thrombocytopenia in SLE. More recently, a copy number variation in FcgRIIIb has also been associated with SLE, it was also reported that increased copy number (CN) was protective and decreased CN was a risk factor.
T-helper cell (Th) cytokines Interferon-a (IFN-a) is a pleiotropic type I IFN with the potential to break immunologic self-tolerance by activating antigen-presenting cells after uptake of self-material. Moreover, IFN-a promotes long-term antibody production, class switching and immunological memory. Several sets of compelling data suggest an important pathogenic role for IFN-a in SLE, and papers published as early as 1979 have described increased serum levels of IFN-a in patients with SLE, particularly those with active disease. IFN-g plays a key role in the development of autoimmune processes. More than 32 years ago, Hooks et al. 23 found IFN-g in the sera of patients with SLE and showed a good correlation between immune IFN-k titers and disease activity. It is likely that excessive induction of IFN-g gene expression upregulates IgG production by mononuclear cells in patients with SLE, which may enhance disease development. 24 It is also noteworthy that many IFN-regulatory factors are also strongly associated risk factors for SLE because they can induce transcription of IFN-a mRNA. Graham et al. 25 identified that the rs2004640 SNP of IRF5 is a risk factor for SLE. Further support for this finding comes from a genome-wide association study in individuals of European, African and Asian ancestry. [26] [27] [28] Lö fgren et al. 29 recently genotyped IRF5 using the CGGGG insertion/ deletion and the rs2004640, rs2070197 and rs10954213 SNPs in 1488 SLE patients and 1466 healthy controls. They showed that rs10954213 is the main SNP responsible for altered IRF5 expression in the peripheral blood mononuclear cells (PBMCs). Hikami et al. 30 found that a functional polymorphism in the 3 0 -untranslated region (UTR) of SPI1, which is known to regulate expression of IRF2, IRF4 and IRF8, 31, 32 plays a potential role in predisposing to SLE. The IRF7 gene can also stimulate induction of IFN-a RNA. 33 Harley et al. 6 reported that there was a significant association between SLE risk and locus between IRF7 and the PHRF1 gene in a European population. Moreover, recent studies have shown that the risk allele of STAT4 was significantly associated with increased sensitivity to IFN-a signaling in lupus patients. 34 SLE patients who carry the STAT4 risk variant have increased expression of downstream IFN-I-regulated genes in vivo as compared with patients who do not carry the allele. 35 It was also reported that rs7574865, a variant allele of STAT4, is strongly associated with SLE characterized by double-stranded DNA autoantibodies. 34 Tumor necrosis factor-a (TNF-a) gene is located on chromosome 6 (6p21.31), within the class III region of major histocompatibility complex. 36 TNF-a is a ubiquitous cytokine that plays an important role in various physiologic as well as pathologic processes such as inflammation, immunoregulation, proliferation and apoptosis. 37 It has two differing actions in SLE. On one hand, TNF-a could be an immunosuppressive mediator of autoantibody synthesis, and on the other hand, TNF-a might be a proinflammatory factor acutely released in the local tissues. Several SNPs have been identified in the TNF-a promoter. 38 Among these, a G-to A-substitution at position À 238 (TNF-a À 238 G4A, rs361525) has been associated with SLE, 39 especially in the Caucasian population. Another SNP of TNF-a promoter is the G-to-A substitution at position À 3008 (TNF-a À 308 G4A, rs1800629). A recent meta-analysis of TNF-a promoter À 308A/G polymorphism has concluded that the A allele contributed to susceptibility to SLE in Caucasians but not in Asians. 40 It is also noteworthy that TNF-a is a pleiotropic inflammatory cytokine whose effects are mediated through two distinct cell surface receptors, TNF-RI (TNFRSF1A) and TNF-RII (TNFRSF1B). 41 A polymorphism at position 196 (a methionine-to-arginine substitution; M196R) of TNFRSF1B was significantly associated with an increased risk of SLE. 42 Moreover, Graham et al. 43 utilized family-based and case-control approaches to identify a risk allele upstream of TNFS4, which is responsible for increased TNFSF4 expression and predisposes to SLE. Moreover, a number of polymorphisms in TNF a-induced protein 3 (TNFAIP3) have also been associated with increased susceptibility to SLE. 44, 45 TNFAIP3-interacting protein 1 (TNIP1) is also identified by genome-wide association study as significantly correlated with SLE in the European and Chinese populations. 26, 46 Moreover, IL10 is also an attractive positional candidate gene as it maps in 1q32 because it is a potent stimulator of B cells and has a direct effect on B-cell survival and autoantibody production. B cells and monocytes of SLE patients produce an increased amount of interleukin-10 (IL-10) compared with nonaffected individuals, and many lines of evidence suggest interleukin-10 production level to the SNP haplotypes. SNPs located more distally in the 5 0 flanking region were tested for association with SLE. A genome-wide association replication study by Gateva et al. 47 confirmed that rs3024505, a variant allele of IL10, is strongly associated with SLE in individuals of European ancestry (P ¼ 3.95 Â 10 À 8 ). Herein, it would also be necessary to show that some other genes encoding IL protein have also been associated with SLE, including IL12 and IL18, 48, 49 which are involved in the onset and progression of SLE.
Other susceptibility genes The programmed cell death 1 (PDCD1) gene located within 2q37 encodes an inhibitory immunoreceptor of the CD28/CTLA4/ICOS family that has a pivotal role in peripheral tolerance. 50 Pdcd1 À / À mice have been shown to develop arthritis and lupus-like glomerulonephritis. A recent study of 2500 individuals has shown association between an intronic SNP in PDCD1 and SLE susceptibility, conferring a 2.6-fold increased risk to Europeans and a 3.5-fold increased risk to Mexicans. 51 Indeed, PDCD1 has in many studies been shown to be associated not only with SLE, but also rheumatoid arthritis, type I diabetes and multiple sclerosis. [52] [53] [54] [55] C-reactive protein (CRP), a pentraxin, is an innate immune modulator that facilitates the clearance and handling of cellular debris and apoptotic bodies. 56 It is an important liver-derived acute-phase protein that can increase up to 1000-fold in serum as a response to diverse stimuli such as infection or injury. Some studies have suggested that SLE is characterized by lower CRP levels than would be predicted. 57 Further studies by Edberg and other investigators 58, 59 have shown that CRP levels are influenced by genetic variation in the CRP promoter. In multiple independent study populations, including both African-Americans and Caucasians, the variation in the CRP promoter at CRP-707 (rs3093061) strongly and reproducibly associates with the SLE phenotype.
PTPN22 gene encodes the cytoplasmic lymphoid-specific phosphatase (Lyp). A functional PTPN22 1858C4T (R620 W) polymorphism (rs2476601) confers significant risk for autoimmune disease. Underlying this association, there are several different mechanisms with different evidences. [60] [61] [62] [63] [64] [65] Some groups have established the possibility that the R620W amino-acid change disrupts binding of Lyp to Csk, 60, 61 thereby disturbing the regulation of the T-cell receptor (TCR)-signaling kinases, Lck, Fyn and ZAP-70. Studies by Menard et al. 64 revealed that the association strength of PTPN22 for autoimmunity may be due to not only impaired removal of autoreactive B cells, but also upregulation of genes such as CD40, TRAF1 and IRF5. Moreover, Zikherman et al. 65 demonstrated that PTPN22 deficiency cooperates with the CD45 E613R genetic background to provoke autoantibody production and a lupus-like autoimmune disease. Genetic studies with different populations revealed a different frequency of the disease-associated 1858T allele in Europe, [66] [67] [68] but not associated with SLE in the Norwegian and Turkish populations. 69 In contrast to the R620W SNP, a rare missense substitution (R263Q) in PTPN22 was shown to reduce phosphatase activity and was associated with protection from SLE. 70 In addition, Manjarrez-Orduno et al. 71 recently reported an association of CSK with SLE and refined its location to the intronic polymorphism rs34933034 (odds ratio ¼ 1.32; P ¼ 1.04 Â 10
). The risk allele at this SNP is associated with increased CSK expression and augments inhibitory phosphorylation of Lyn. In carriers of the risk allele, there is increased B-cell receptormediated activation of mature B cells, as well as higher concentrations of plasma IgM relative to individuals with the nonrisk haplotype.
Moreover, it is noteworthy that recent genome-wide association and candidate gene studies have identified many additional risk loci. 6, 46, 47 These include genes encoding proteins important for the biological role of Toll-like receptor/IFN-I and lymphocyte signaling in the pathogenesis of SLE (UBE2L3, IKZF1, MECP2, ATG5, PRDM1 and ETS1) and proteins with roles in lymphocyte development and signaling (BLK, RASGRP3, BANK1), and proteins participating in other/not known immune function (JAZF1, PXK, PTTG1, LRRC18-WDFY4, DDX6, SLC15A4, UHRF1BP1). In summary, the rapidly growing catalog of loci associated with SLE represents a key early step in our understanding of this disease; however, the vast majority of the genetic burden of this disease has yet to be discovered.
EPIGENOMICS RESEARCH OF SLE
Regardless of a growing number of known predisposing alleles, not all carriers develop clinical disease. Patients with the same or similar alleles might present with different disease course, and the prevalence of SLE in monozygotic twins is 25-45%. 72 Thus, environmental factors appear to influence disease onset, progression and outcome. 73 Epigenetic modifications can influence gene expression, thereby altering cellular function without modifying the genomic sequence in response to a variety of environmental stimuli. By defining the set of genes that are competent for expression and the set of genes that are repressed, the character of the cell is determined largely by the epigenomics. 73 Three main epigenetic processes are in the center of epigenetic control: DNA methylation, nucleosome repositioning by histone modifications and microRNAs (miRNAs). 74 
DNA methylation
The most widely researched epigenetic modification to date is DNA methylation. Cytosine methylation of the regulatory sequences of DNA is associated with transcriptional inactivation of genes, whereas hypomethylation contributes to the activation of transcription. Accumulating evidence indicates that lymphocytes of SLE patients exhibit globally hypomethylated DNA. 75, 76 DNA fragments isolated from the plasma of SLE patients contain B1% of methylcytosine, whereas genomic DNA of healthy individuals contains 2.5-4.5% of methylcytosine. Variable methylation of ribosomal genes was reported whereby 18S and 28S ribosomal subunit genes are hypomethylated in lupus individuals of discordant pairs and hypomethylated in both individuals of concordant lupus twin pairs examined. Remarkably, the PBMCs of SLE patients display a lower transcript level and enzymatic activity of DNMT1 (DNA (cytosine-5)-methyltransferase 1) than PBMCs isolated from the blood of healthy individuals, which is further verified by the report that demethylating agents, including 5-azacytidine, procainamide and hydralazine, can induce lupus-like features in both animal models and human T lymphocytes. 74, 77, 78 A generally hypomethylated state of T-and B-lymphocyte genes has been reported in SLE patients. It is thought that the overexpression of these methylation-sensitive genes leads to T-cell autoreactivity and subsequent induction of autoreactive B-cell immunoglobulin production. It is noteworthy that Jeffries et al. 79 utilized high-throughput methylation arrays to analyze the methylation status of over 27 000 CpG sites in promoter regions of nearly 15 000 genes for 12 female lupus cases and 12 controls. They found hypomethylation of 236 CpG sites and hypermethylation of another 105 sites. The hypo-methylated genes, including ADAMTS1, ALX4, CD9, ESRRA, FGF8, HOXA13, HOXD11, MMP9, MSX1, PDGFRA and SOX5, are involved in connective tissue development, whereas the hyper-methylated genes are involved in folate biosynthesis.
Although the mechanisms for the occurrence of DNA hypomethylation in patients with active lupus are not fully addressed, there are three possible mechanisms account for this. One Applied basic research of SLE W Sui et al possibility is that GADD45a is suspected to promote demethylation by interacting with MBD-4 and AID 78, 80 (Figure 1) . A second possibility is that the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway can regulate DNMT levels. 74, 78 In addition, it is important to note that the TF RFX1 plays an important role in the molecular mechanisms. RFX1 binds to promoter regions of target genes and recruits the corepressors DNMT1 and histone deacetylase 1, consequently suppressing target genes. However, in lupus T cells, decreased levels of RFX1 at CD11a and CD70 promoters leads to decreased methylation and increased expression of both of these genes in lupus CD4 þ T cells via reduction in DNMT1 and histone deacetylase 1 recruitment, which results in lupus-like T-and B-cell hyperactivity. 81 Histone modifications Histone complexes possess flexible N-terminal tails that are accessible to posttranslational modifications and strongly affect the functional capacities of nucleosomes. 74 They include not only acetylation and methylation of the protruding histone tails but also phosphorylation, ubiquitylation, sumoylation, citrullination, ADP ribosylation and proline isomerization. 82 Each histone tail modification occurs on specific residues and acts globally to tighten or relax the chromatin surrounding a particular gene, thereby regulating access of the transcription complex. In recent years, increasing evidence has suggested that histone modifications are related to the pathogenesis of SLE. Among these, histone lysine methylation is one of the most important epigenetic modifications. Aberrant alterations in histone lysine methylation patterns that change chromatin structure could lead to dysregulated gene transcription and disease progression. Dai et al. 83 adopted chromatin immunoprecipitation linked to microarrays (ChIP-chip) technology to profile and compare the variations in H3K4me3 at the genome-wide level of PBMCs from SLE patients and healthy controls. They found that two key relevant genes PTPN22 and LRP1B showed a significant decrease in histone H3K4me3 in active and inactive SLE patients as compared with healthy subjects. In addition, histone acetylation is associated with competence for transcription and histone acetyl transferases are recruited by many TFs. H4 acetylation, for example, participates in the transcriptional regulation of inducible genes. 84 Zhang et al. 85 found that H4 acetylation was significantly increased in monocytes from patients with SLE as compared with controls.
It appears that increased histone modification is a doubleedged sword. For instance, acetylation of histone tails leads to an open conformation of chromatin that is permissive to gene expression. Mice with a B cell-specific knock-in mutant version of p300 that lacks only histone acetyltransferase activity develop a lupus-like autoimmune disease characterized by splenomegaly, nephritis and vasculitis. 86 On the other hand, triacetylated histone H4 is capable of modulating disease in MRLlpr mice, enhancing mortality, proteinuria, skin lesions and glomerular deposition of antibody-antigen complexes, whereas the unmodified protein had no such effects. 87 Moreover, it is possible that the apoptosisinduced chromatin modifications are an initial event that results in disruption of the immune tolerance to self and formation of pathogenic chromatin autoantibodies in SLE.
MiRNAs
The miRNAs are endogenous 21-25 nucleotide noncoding RNA molecules that are potent negative regulators of gene activity. 88 Recent studies have shown that miRNAs regulate the function of both the innate and adaptive immune system, which are involved in various immune pathways, 89 and could potentially serve as disease biomarkers and therapeutic targets. 90 Altered miRNA expression has been reported in human autoimmune diseases including SLE. 91 Dai et al. 92 comprehensively analyzed miRNAs in the PBMCs of SLE patients by using miRNA microarray. They identified 16 SLE-related miRNAs, with 7 miRNAs downregulated and 9 miRNAs up-regulated in SLE PBMC. Subsequently, they further compare the miRNA profile of kidney biopsies between N patients and controls. 93 They found 66 miRNAs in renal samples, of which 30 miRNAs were downregulated and 36 miRNAs upregulated in LN biopsies. In this regard, many miRNAs have been identified based on their possible pathogenic roles. For example, miR-21 regulates aberrant T-cell responses through regulation of PDCD4 expression in SLE. 94 miR125a contributes to elevated levels of the inflammatory chemokine RANTES (regulated and normal T cell expressed and secreted) in SLE, via targeting of KLF13. 95 In addition, the knocking down of miR-126 in SLE CD4 þ T cells decreased their autoimmune activity and their stimulatory effect on IgG production in the co-cultured B cells. 96 MiR-146a is a negative regulator of the IFN pathway, and underexpression of miR-146a conduces to alterations in the type I IFN pathway in lupus patients by targeting the key signaling proteins (Toll-like receptor 7). 90 Moreover, it is important to note that miRNAs have a close relationship and complex interplay with DNA methylation and histone modifications. On one hand, histone modifications and DNA methylation can regulate the expression of certain miRNAs. Figure 1 . Methylated CpG (CmpG) demethylation by GADD45a. DNA demethylation may occur through a two-step enzymatic process, promoted by GADD45a. The first step involves deamination of CmpG nucleotides by activation-induced deaminase (AID), generating a thymine product and a G:T mismatch. The second step involves thymine base removal by methyl-CpG-binding domain 4 (MBD-4). In the following, the missing base is replaced by a nonmethylated cytosine group, resulting in demethylation of CmpG dinucleotides. 80 Applied 97 found that miR-142 À 3p/ À 5p is downregulated in SLE CD4 þ T cells because of a deregulation of histone methylation (H3K27me3) and DNA methylation in its promoter. Subsequently, the decreased miR-142 À 3p or miR-142 À 5p can increase CD84 and IL-10 or SAP (stress-activated protein) protein levels, respectively, which contributes to aberrant T-cell responses and B-cell hyperresponsiveness in SLE. On the other hand, miRNAs can affect DNA methylation and histone modifications by targeting methylase and acetylases enzymes directly. Zhao et al. 96 report that miR-126 correlates with decreased DNMT1 expression by interaction with the 3 0 -UTR region of DNMT1 in SLE CD4 þ T cells. 98 TFs interact with specific DNA-binding elements presented in the promoters of certain genes to promote transcriptional initiation. Defects in TF regulation, structure and function play critical roles in the development and function of the immune system. 99, 100 Accumulating evidence has suggested that the TFs with differences in expressions and activity may be potential novel biomarkers or help to illuminate pathogenic mechanisms of complex genetic diseases such as SLE.
TRANSCRIPTOME RESEARCH OF SLE
As a group of crucial components in the interconnecting regulatory networks, TFs play a central role in regulating gene transcription and expression. Analysis of the human genome sequence predicts there may be as many as 1850 human TFs.
Aberrant expression of TFs
In order to reveal the relationship between SLE and TFs, Sui et al. 101 compared the levels of TF expression by microarray technology in the PBMCs of SLE patients with normal controls. In the study, a total of 345 TFs were identified, with 92 of them differentially expressed, in which 78 TFs were upregulated and 14 TFs downregulated in SLE as compared with the control group. They further indicated that TFs such as activator protein-1 (AP-1), Pbx1 and myocyte enhancer factor-2 (MEF-2) were potential diagnosis biomarkers and probable factors involved in the pathogenesis of SLE. Considering that the important role of FOXOs in controlling lymphocyte activation and immune functions. Kuo et al. 102 evaluated the transcript profiles of FOXO1, FOXO3a and FOXO4 genes in PBMCs from SLE and RA patients as compared with healthy controls. Their results showed that transcript levels of FOXO1, but not of FOXO3a or FOXO4, were significantly downregulated compared with normal controls and correlated with lupus disease activity. It suggests that the transcriptional dysregulation in FOXO1 is possibly linked to the pathogenesis of SLE and rheumatoid arthritis. Additionally, Burgos et al. 103 found that significantly increased levels of c-Rel (a member of nuclear factor (NF)-kB/Rel family of TFs) mRNA were found in PBMCs from SLE patients. It is noteworthy that estrogen induces serine protease-mediated proteolysis of signal transducer and activator of transcription 1 (STAT-1) and NF-kB. 104 In this way, estrogen enhances STAT-1 DNA binding activity without increasing the expression of phosphorylated and total STAT-1 protein. Subsequently, the modified STAT-1 and NF-kB proteins in splenocytes from estrogen-treated mice have differential roles in regulating different inflammatory molecules.
Abnormal gene transcription Imbalance in the cytokines produced by the two subsets of T-helper cells, Th1 and Th2, probably plays an important role in the pathogenesis of SLE. 105 T-bet and GATA-3 are the principal TFs for the differentiation of Th1 Th2 lymphocytes, respectively. Lit et al. 106 found significantly increased mRNA levels of T-bet and IFN-g and decreased mRNA levels of GATA-3 and IL-4 in SLE patients, which correlated with lupus disease activity, and there was a significant correlation in mRNA expression of T-bet with IFNg, and of GATA-3 with IL-4. These findings were further confirmed by Chan et al. 107 Moreover, recent studies have shown that a risk haplotype of STAT-4 for SLE is overexpressed. Several TFs, including AP-1 and NF-kB, have been found to increase STAT-4 expression by interacting with its promoter. 108 STAT4 plays a key role in type I IFN receptor signaling that results in type I IFN over-expression and contributes to the disease pathogenesis of SLE. The TF IRF5 is also a major mediator of Toll-like receptortriggered expression of proinflammatory cytokines such as type I IFN and TNF-a. 100 IRF5 could also promote expression of the STAT4 gene in the same way; thus, both STAT4 and IRF5, which are functionally linked, contain polymorphisms that confer increased risk for SLE.
In addition, NF-ATc2 regulates CD154 and IL-2 gene transcription by binding to the promoters. Juang et al. 109 present evidence that NF-ATc2 is increased in the nuclei of activated SLE T cells, which results in increased CD154 and decreased IL-2 transcription in patients with SLE. The explanations for these discrepancies may be that the transcriptional repressor CREM (cyclic AMPresponse element modulator)-mediated AP-1 (c-fos/c-jun heterodimer) deficiency in SLE T cells leads to the null effect of upregulated NF-AT on the transcription of IL-2. The decisive elements for the transcription of the IL-2 lie within 300 bp upstream of the start codon of the IL-2 gene promoter, including AP-1 sites, NFAT sites, NF-kB site and CREM/CREB site and others. PP2A is the primary enzyme that leads to dephosphorylation of pCREB in T lymphocytes, 110 and PP2A-mediated dephosphorylation at SP-1 serine 59 is critical for CREM P1 promoter activity. In SLE T cells, the overexpressed PP2A contributes to decreased levels of pCREB and increased levels of dephosphorylated SP-1, and the dephosphorylated SP-1 drives increased expression of CREM through the CREM P1 promoter. 111 It is conceivable that the decreased pCREB and increased CREM may permit CREM to occupy their common À 180 binding site on the IL-2 promoter and directly suppress IL-2 production. 112 Moreover, CREM binding to the c-fos promoter in unstimulated live T cells from SLE patients is significantly increased. Increased binding results in decreased transcription of c-fos gene, decreased production of c-fos protein and AP-1 (c-jun/c-fos dimmers) binding in the nuclei of SLE T cells. In this regard, a lack of NFkB activity, particularly the function provided by the p65 subunit, also provides a mechanism for a defect in IL-2 expression. Taken together, decreased expression of the transcriptional enhancers NF-kB, pCREB and AP-1, as well as increased expression of the transcriptional repressor CREM, leads to decreased production of IL-2 in SLE T cells. The above information suggests that the interaction and coexpression between TFs and cytokine provide positive and negative feedback regulation for Th1 and Th2 development.
POSTTRANSCRIPTIONAL REGULATION OF SLE
Recently, a widespread incidence of A-to-I editing of Alu-containing and intronic regions of pre-mRNAs in the human transcriptome has been identified in patients with SLE. 113 Messenger RNA editing induced by ADARs (adenosine deaminases acting on RNA) and other editing enzymes is a process defined as the co-or posttranscriptional modification of mRNA through nucleotide substitutions, insertions and deletions, which play a pivotal role in the regulation of gene expression and in pathophysiology. 114, 115 In addition to RNA editing, alternative splicing is also a powerful mechanism of gene regulation. In this way, a single human gene can produce a variety of protein products with related yet distinct functions that may allow cells of different types or at different developmental stages to perform different tasks. However, aberrant mRNA editing and splicing could cause the cells to 119 demonstrated the occurrence of altered mRNA editing profile of PDE8A1, ADAR2 and a regulatory subunit of protein kinase A (RIa) gene transcripts in SLE T cells, which has been confirmed by the absence of such mutations in genomic DNA. They observed A-to-I hypoediting at known sites of PDE8A1, specifically in T cells derived from SLE patients and in normal T cells activated with type I IFNs. Similarly, altered editing at known sites and novel editing sites in the ADAR2 gene products was uncovered, including decreased editing of the þ 23 and þ 24 sites from A to I and increased editing of À 6 and þ 30 from U to C in SLE T lymphocytes. Notably, the results of sequenced cDNA of RIa and corresponding genomic DNA of the coding region showed that there was 1.22 Â 10 À 3 /bp transcript mutation in SLE T cells-a frequency 7.5 times higher than that in control T cells. Furthermore, Toyabe et al. 115 found that there are increased nucleotide substitutions and deletions of DAP12 mRNA in natural killer cells from SLE patients, which results in decreased expression of DAP12. Wu et al. 120 found that a novel FAS mRNA mutation is significantly increased in SLE; this FAS mRNA mutation is caused by a site-specific editing process, in which an adenine is inserted at a defined location that leads to the production of a novel defective FAS receptor (edFAS) (Figure 2 ). It was interesting to note that the increased editing was accompanied by an increased expression of ADAR1; ADAR1 mRNA content 3.5 times higher in SLE T cells than in control T cells has been reported. An explanation for the abnormal mRNA editing is that high circulating levels of IFN-a upregulate IFN-inducible 150 kDa ADAR1 transcript levels in SLE patients, which results in increased ADAR1 enzymatic activity, 121 and suppression of ADAR2-catalyzed transcript editing, thus leading to increased or decreased editing of gene transcripts induced by different ADARs. These pathological RNA editing of genes account for aberrant gene expression and signal transduction and, ultimately, impaired immunity in SLE pathogenesis. For instance, mutant RIa transcripts are pathophysiolgically significant, for they can encode diverse and aberrant RIa isoforms, including truncated and dominantnegative subunits, which result in deficient type 1 protein kinase A (PKA-I) activity. As we know, PKA isozymes phosphorylate multiple intracellular substrates, including plasma membrane proteins, intracellular receptors and TFs. [122] [123] [124] We propose that deficient PKA-I isozyme activity contributes to the pathogenesis of SLE by hindering effective signal transduction and impairing T-cell effector functions. Similarly, aberrant FAS mRNA editing results in the production of a defective FAS receptor, which is unable to mediate apoptosis signal. 125 Alternative splicing Alternative splicing is also a powerful mechanism of gene regulation that conduces to the generation of numerous transcripts and proteins from a single gene. 126 Moulton and Tsokos 127 and other investigators identify ASF/SF2 (alternative splicing factor/splicing factor 2) as a novel factor that binds to the 3 0 -UTR of CD3z in the regulation of alternative splicing and protein expression in SLE patient T cells. The CD3z mRNA is a 1.472-kb spliced product of the eight exons with a coding region of 492 bp and an exon VIII-encoded long downstream 906-bp 3 0 -UTR. The reverse transcriptase-PCR analysis of the TCRz chain 3 0 -UTR showed an alternatively spliced (AS) 344-bp product with both splicing donor and acceptor sites. It was suggested that activation of alternative splicing within the 3 0 -UTR due to usage of two internal splice sites (5 0 and 3 0 ) leads to splice deletion of 562 bases (nucleotides 672-1233) of the TCRz chain mRNA, which results in the generation of a 344-bp AS variant. Therefore, SLE T cells exhibit variably increased levels of the AS isoform, 128 whereas T cells from healthy individuals express mainly the wild-type isoform. Although this alternative splicing just affects the UTR and not the coding region, the 344-bp AS CD3z isoform lacks a translation regulatory sequence and two key regulatory adenosine/uridine-rich elements. Thus, the transcript stability and translation of AS isoform are significantly lower than that of the 906-bp wild-type CD3z isoform. Consequently, the relative amount of CD3z protein generated by the AS isoform is significantly lower than that from the wild-type isoform, 129 which can explain why the TCR-associated CD3z chain is decreased in SLE patients. In addition to CD3z gene, abnormal expression of AS isoforms of other genes is frequently observed in patients with SLE, including the adhesion molecule CD44 and the TF CREM. 130, 131 PROTEOMICS OF SLE Protein is the executor of physiological function. As we enter the postgenomics era, 132 proteomics has been implanted into almost every field of life sciences and medicine. The feasibility of proteomics technology with multiple samples is ideally suited for investigating the complicate alteration of proteomics in patients with SLE, which may help to find new biomarkers that can be used to reliably confirm SLE or monitor their progression with high sensitivity and specificity. Using this method, we can better understand the pathogenesis, diagnosis and treatment for SLE.
Proteins in PBMCs
Dai et al. 133, 134 identified an overall pattern of differentially expressed proteins profiles in PBMCs of patients with SLE as compared with healthy controls. In 2008, they found that 20 proteins are differentially expressed in the PBMCs of patients with SLE. 133 Among these, 11 protein spots were upregulated and 9 protein spots were downregulated, and 5 differentially expressed proteins were identified as immunoglobulin J chain, apolipoprotein A-IV precursor, calprotectin L1H, zinc-finger protein subfamily 1A (all upregulated) and glutathione S-transferase (GST; downregulated). As described here, it is worthwhile to mention that GST is involved in the detoxification of reactive oxygen species, and genetic polymorphisms of GSTM1, GSTT1 and GSTP1 Applied basic research of SLE W Sui et al are associated with altered enzyme activity and susceptibility to SLE. In order to further investigate the altered proteins profiles in SLE, a total of 452 proteins involving different biological functions and cellular locations were identified by them in 2010. 134 Their experimental results revealed that 67 unique proteins were observed with twofold or more alteration in levels across groups. Comparative proteome analysis differentiating active from inactive SLE revealed 17 upregulated and 13 downregulated proteins. Notably, STRAP (serine/threonine kinase receptor-associated protein) was found to reduce more than threefold in active SLE patients in contrast to the healthy controls, and was inversely correlated to the SLE disease activity. The possible molecular mechanisms of action of STRAP are related to its interaction with the TGF-b receptor or apoptosis signalregulating kinase 1. 135 Serum proteins Human serum contains thousands of proteolytically derived peptides that may provide a robust correlation of the physiological and pathological processes in the entire body. Measuring panels of peptidome markers might be more sensitive and specific than conventional biomarker approaches. Previous studies from the laboratories of Huang et al. 136 and Dai et al. 137 demonstrated differentially expressed disease-related and condition-specific peptides in sera from patient with SLE to develop and validate the peptide classification model for the diagnosis of SLE. The experimental results of Huang et al. 136 exhibited 60 differential proteins peaks (Po0.05) between SLE and control subjects, 28 of which were upregulated and 32 downregulated in SLE patients. Notably, a cluster of four proteins at m/z 3376.02, 4070.09, 7770.45 and 28045.10 segregate SLE from non-SLE with a sensitivity of 91% and a specificity of 92%. Similarly, the experimental results of Dai et al. 137 show that individuals with active SLE, stable SLE and rheumatoid arthritis shared 23 significantly differentiated peptides compared with normal controls, including 10 downregulated and 13 upregulated peptides. Among them, four peptide ion signatures (m/z 3192, 3263, 4268 and 5754) achieved a recognition capacity of 95.74% and a cross-validation of 89.82% to discriminate active SLE from healthy control samples, and a group of peptides at m/z 2661, 2863, 3263 and 5754 separated stable SLE effectively from normal controls with a recognition capacity of 96.30% and a cross-validation of 78.08%. Based on this information, we can infer that proteomics is effective in facilitating the construction of a sensitive and specific diagnostic model. Urine proteins LN is a serious and frequent complication of SLE. Urine proteins that are differentially expressed during renal flare may be the novel and predictive biomarkers of LN. Several SLE nephritis studies examined the urine proteome by surface-enhanced laser desorption/ionization (SELDI) platform and produced encouraging results. [135] [136] [137] One reported two protein ions at m/z 3340 and 3980 that together segregated active nephritis from inactive nephritis with sensitivity and specificity of 92%, but the actual peptides were not identified. 138 Another group of investigators found eight protein ions, which correlated with renal disease activity; most of these were 420 kDa and mostly unidentified, but one seemed to be albumin. 139 Zhang et al. 140 used SELDI time-of-flight mass spectrometry to examine the low-molecular-weight proteome of serial lupus urine samples. They found that there are 27 protein ions differentially expressed between specific flare intervals. Altered protein ions were identified as 20/25 amino-acid isoforms of hepcidin, fragments of a1-antitrypsin (A1AT) and albumin. Hepcidin 20 (m/z 2198) increased 4 months before flare and then gradually returned to baseline by 4 months post flare, implying it may be a useful marker of impending renal flare, whereas hepcidin 25 (m/z 2432) decreased at renal flare and then returned to baseline by 4 months post flare, suggesting it may be a biomarker for following response to therapy.
Tissues proteins
Cytokeratins are major structural proteins specifically expressed in epithelial cells, in which they form intermediate filaments. 141 Cytokeratins are encoded by a large multigene family, and are classified as type I keratin 9 (K9 À K20) or type II (K1-K8). It is of importance that an alternative pattern is open to keratinocytes in response to epidermal injury or certain skin disorders. 142, 143 Fang et al. 144 used a proteomics approach to clarify the abnormal expression of cytokeratins in lesions from SLE patients. Their result showed 16 protein spots that were upregulated and 9 that were downregulated in SLE lesions in contrast to the normal epidermis. Among them, K1 and K10 were downregulated in SLE lesions whereas K2e, K5, K6, K14, K16 and involucrin were obviously upregulated. Especially, K6 was only expressed in SLE lesions but not in normal skin. In addition, the distribution of protein also presented an altered pattern between SLE and control subjects. For instance, K5 and K14 were not only limited to basal cells but to suprabasal cells, whereas K5/K14 were limited to basal cells in normal epithelia. Similarly, Sui et al. 145 utilized iTRAQ (isobaric tags for relative and absolute quantitation) technology to analyze the total proteins of renal tissue in patient with LN. In their study, a total of 490 distinct proteins involving different biological functions and cellular locations were identified. Of these, 113 proteins were upregulated or downregulated at onefold or more alteration in levels as compared with normal controls. Four proteins showed significant deviation, and they are identified as argininosuccinate synthetase (ASS), aldolase (all downregulated), heterogeneous nuclear ribonucleoprotein (hnRNP-) and annexins (all upregulated).
PROTEIN MODIFICATION OF SLE
Classical biochemistry tells us that 20 amino acids make up most of the proteins in nature. However, it is noteworthy that between 50 and 90% of the proteins in the human body acquire PTM. The most frequently observed PTMs include phosphorylation, glycosylation, acetylation, ubiquitination and citrullination. PTMs alter various aspects of the protein chemistry, including primary and tertiary structure, biological (and/or enzymatic) functions and proteolytic degradation that may be decisive in generating immunogenic or tolerogenic self-peptides. Accumulating evidence suggests the involvement of PTMs in the pathophysiology of SLE.
PTMs with aberrant signaling Phosphorylation of proteins on tyrosine, serine or threonine by protein kinases is a key biochemical process in intracellular signaling. Taher et al. 146 applied the kinome array technique to generate a kinase profile of B lymphocytes from SLE patients and healthy controls. They found that there were changes in the phosphorylation pattern in B lymphocytes from a majority of the SLE patients, with an increase in the phosphorylation of 27 target substrates and a decrease in the phosphorylation of 34 target substrates relative to controls. Their results further indicate that the activity of phosphatidylinositol 3-kinase, MAP, Rho, FAK, ASK-1, CDK-1, PKC, PKA, Tec and the cell cycle kinase ATR was altered in SLE patients. Among them, phosphatidylinositol 3-kinase activity was increased, which regulates survival and differentiation. The activity of ATR, which regulates the cell cycle, was decreased in SLE patients in contrast to controls.
Additionally, T cells from patients with SLE are characterized by decreased expression of CD3z chain and increased expression of FcRg chain, which contributes to aberrant signaling. 147 Abnormal PTMs of TFs can account for this deregulation. The TF EIf-1 is 148, 149 However, in SLE T cells, the 80-kDa EIf-1 protein does not undergo proper posttranslational modification, which results in decreased levels or absence of the 98-kDa form. Elf-1 is a TF that can serve as a transcription activator or suppressor. 150 Decreased blinding of EIf-1 to the CD3z and FcRg promoters is associated with decreased expression of CD3z and increased expression of FcRg in SLE T cells.
PTMs with self-antigens It is clear from the literature that PTM of self-proteins is an important explanation of how immune tolerance is lost to selfantigens (Figure 3) . [151] [152] [153] Several sets of compelling data have suggested that modified self-antigen influences immune recognition, whereas lack of a normally occurring PTM within a self-antigen may also induce autoimmunity. For instance, the sera of SLE patients contain autoantibodies to both nonphosphorylated and phosphorylated SR proteins (pre-mRNA splicing factors). 154 In this regard, Utz et al. 152 and other investigators 155, 156 have shown that cells undergoing apoptosis are uniquely suited to present modified self-proteins to the immune system in such a way that it overcomes normal mechanisms of peripheral tolerance. It was also revealed that proteins modified during apoptosis may also be preferred targets for autoantibody production. 154, 157 For instance, SAP kinase in phosphorylation of autoantigens during apoptosis connects a common protein modification with autoantibody production in SLE patients.
Moreover, several studies have suggested that PTMs and especially phosphorylation and citrullination can influence autoantibody binding onto different autoantigens in patients with SLE. Terzoglou et al. 158 showed that phosphorylation of the linear B-cell epitope 349-368aa of La autoantigen/Sjogren syndrome antigen B (La-SSB) autoantigen enhances its relative avidity and autoantibody binding. They also demonstrated Ro60 kDa autoantigen contains two linear B-cell epitopes, spanning the sequences 169-190aa and 211-232aa. 159, 160 The epitope 169-190aa was recognized mainly from sera of SLE patients, and this sequence contains two arginine and one serine amino-acid residues, which can potentially be modified posttranslationally by citrullination or phosphorylation, respectively. Their experimental results showed that PTMs of the B cell epitope 169-190aa of the autoantigen Ro60 kDa can decrease recognition of this epitope by autoantibodies found in the sera from patients with autoimmune diseases including SLE. In this regard, other investigators discovered that the aberrant N-glycosylation on the kidney proteins of a SLE model mouse. 161 The mice lacking the gene for a-mannosidase II, which regulates hybrid to complex branching patterns of extracellular asparagine (N)-linked oligosaccharides chains (N-glycans), develop a lupus-like nephritis characterized by autoantibodies to histones, Sm snRNP (small nuclear ribonuclear protein) antigen, and DNA. It is thought that the lack of complex N-glycan branching may affect selfantigen recognition. Although the mechanisms are not fully addressed, these observations can be explained in three ways. First, the modified residues may conduce directly to antibody binding and a possible modification of one or more of these residues can influence the affinity of the antibodies. Second, the tested PTMs may have affected the secondary structure of the peptides. Third, the existence of these modifications alter the overall electrical charge of the peptides. 160 Taking the La/SSB protein as an example, the 349-368aa La/SSB epitope is highly positively charged (isoelectric point ¼ 10.4), whereas a phosphate Figure 3 . Posttranslationally modified proteins initiate autoimmune responses. Self-proteins can be modified during cellular stress, such as apoptosis, inflammation or aging. These PTM self-proteins are released from apoptotic or necrotic cells, where they are phagocytosed by macrophages and other antigen-presenting cells (APCs); once inside the APC, the existence of these modifications can change how proteases cleave the self-antigen, thus generating new epitopes. These modified peptides are then presented in the context of MHC class II molecules to T and B cells that have escaped the thymus or bone marrow during negative selection because the modified peptide is not present in those organs. Finally, autoreactive T cells and B cells infiltrate host tissue and induce autoimmune pathology. 153 Applied basic research of SLE W Sui et al group has a negative charge. The incorporation of a negatively charged group into a positively charged protein region would be expected to alter the local tertiary structure via ion-ion interactions, 162 eventually affecting anti-La/SSB antibody binding.
METABOLOMICS OF SLE
Alternative biomarker discovery approaches include metabolomics, that is, the systematic study of unique chemical fingerprints or small-molecule metabolite profiles that are the result of specific cellular processes. Nuclear magnetic resonance (NMR) spectroscopy in combination with pattern recognition analytical techniques has grown in popularity for metabolic profiling. Until now, accumulated evidence has suggested that the metabolite profiling is altered in patients with SLE and association with disease activity.
Blood metabolites Recently, Ouyang et al. 163 utilized 1 H NMR spectroscopy-based metabolomics approach to identify the characteristics of metabolite profiling from serum from patients with SLE. In their study, 600 Hz NMR spectroscopy was applied to detect serum of 64 SLE patients and 35 healthy controls. They found that the SLE serum samples were characterized by reduced concentrations of valine, tyrosine, phenylalanine, lysine, isoleucine, histidine, glutamine, alanine, citrate, creatinine, creatine, pyruvate, high-density lipoprotein, cholesterol, glycerol, formate and increased concentrations of N-acetyl glycoprotein, very-lowdensity lipoprotein and low-density lipoprotein in comparison with the control population. Among these, the decreased citrate and pyruvate in serum possibly resulted from meeting the energy charge in the Krebs cycle, which might reflect an increased energy demand relative to the decreased energy availability under inflammatory conditions. The elevated levels of very-low-density lipoprotein and low-density lipoprotein, and lower levels of highdensity lipoprotein, which have been identified as the 'lupus pattern', might be related to the inflammatory process because poly-unsaturated fatty acids (for example, leukotrienes or prostaglandins) are precursors of inflammatory mediators. In this regard, several investigators have further observed that lipid peroxidative damage was significantly increased in SLE, 164, 165 which is a risk factor for cardiovascular disease. Based on these findings, it is likely that SLE mainly influenced energy, amino acid, lipid, and purine nucleotide metabolism. Furthermore, principal component analysis and partial least square discriminant analysis models were established by Dai et al., 163 which was capable of distinguishing SLE patients and healthy controls with a specificity and sensitivity of 97.1% and 60.9%, respectively.
Brains metabolites Involvement of the brain is one of the most important complications of SLE. It is clear from the literature that brain function is closely correlated with glucose utilization because the brain is dependent exclusively on glucose as its sole source of energy. Komatsu et al. 166 evaluated 12 active SLE patients with or without psychiatric symptoms. Their study revealed that psychiatric patients had significantly decreased regional cerebral metabolic rates for glucose in the prefrontal, inferior parietal and anterior cingulate regions. In order to obtain an insight into the dynamics of changes in glucose metabolism, Jessy et al. 167 used 1 H and 13 C NMR spectroscopy to determine the rates of incorporation of glucose into amino acids and lactate via cellspecific pathways in mice with lupus. They found that the MRL/lpr mice had a significant increase of 30-80% (Po0.001) in total brain glutamine, glutamate and lactate concentrations, whereas alanine, aspartate, N-acetyl aspartate and g-aminobutyric acid remained unchanged as compared with the congenic MRL þ / þ control mice. Furthermore, a significant increase in total brain water content was observed, indicative of possible edema. There exists a close correlation between energy metabolism and cell volume regulation in cultured astrocytes. Increased concentrations of different metabolites such as glutamine and glutamate can cause changes in ionic strength and thereby lead to a change in water transport and content. As the brain is in a defined space, waterflux and cell volume are critical and intracerebral swelling can be fatal. Thus, the altered glucose metabolism correlates with brain lesions and behavior in SLE patients. 168 Additionally, a significant increase in lactate concentrations in lupus brains was a result of de novo synthesis from glucose other than pyruvate synthesized from precursors. An increase in lactate has several pathological implications because severe lactic acidosis can result in complete infarction of the tissue and, given its vasodilating effect on cerebral vessels, even at neutral pH levels it may contribute to changes in cerebral blood flow. 169 Thus, an increase in lactate is indicative of brain dysfunction, and the selective changes in brain metabolites and osmolytes may be the underlying cause of neurological disturbances and brain edema that occur in SLE.
Urinary metabolites
In the study of Rosendale et al. 170 they showed that two urinary metabolites, taurine and citrate, were found to accurately distinguish between proliferative LN (class III/IV) and pure membranous LN (class V ) patients. Class III/IV LN patients had 410-fold lower levels of urinary taurine in contrast to class V patients, who had mostly normal levels (Po0.01). Urinary citrate levels were eightfold lower in class V LN in comparison with class III/IV patients, who had normal levels of urinary citrate (Po0.05). Moreover, urinary hippurate levels accurately distinguished between class V patients, who had normal levels of urinary hippurate, compared with focal segmental glomerulosclerosis patients, who completely lacked urinary hippurate (Po0.001). In this regard, previous studies have suggested that taurine and citrate are both measures of tubular cell function. 171 The kidneys filter and reabsorb metabolites to maintain a metabolic equilibrium, and the presence of renal pathologies can impair the filtration of small metabolites such as taurine and citrate through the glomerulus and their subsequent re-absorption in the renal tubules, leading to alterations in metabolic profiles. 172 Bone metabolites More recently, increasing interest has been focused on bone metabolism in patients with rheumatic disorders. 173, 174 A large body of work has demonstrated that SLE is associated with a decreased bone mineral density (BMD), which is related to the severity of the disease rather than to the glucocorticoid treatment. 175, 176 Kalla et al. 177 described that SLE is associated with significant cortical bone loss, and the BMD measured at the lumbar spine or the total femur is reduced. 175 However, other studies have presented inconsistent results. Dhillon et al. 178 did not find a decreased lumbar bone mineral density as assessed by dual-energy X ray absorptiometry. There are several possible explanations for this discordance, such as small sample size and ethnic background. In the study of Hansen et al., 179 BMD and biochemical markers of bone turnover was examined and followed for up to 2 years in a cohort of 36 patients with SLE. They found that the BMD was decreased in the hand and neck but was normal in the spine and distal forearm. Moreover, the serum concentration of the carboxyterminal crosslinked telopeptide of type I collagen was increased in almost all patients. Teichmann et al. 180 found that the reduction of BMD in female patients with SLE was related to the significantly increased excretion of urinary pyridinoline, to hypoparathyroidism, and to the decrease in serum osteocalcin. Moreover, Redlich et al. 181 showed that albumin corrected serum calcium concentrations were slightly but significantly increased in the SLE group. Phosphorus values were found to be significantly lower in SLE patients, but there were no significant differences in parathyroid hormone and 25-hydroxyvitamin vitamin D levels.
CONCLUSIONS
Taken together, the past decades have seen momentous progress in the field of SLE, with a better understanding of the pathophysiology of the disease and the identification of many novel biomarker candidates for disease monitoring and treatment evaluation as well as developing novel strategies for therapy. As described here, we clearly show that multiple susceptibility genes contribute to the development of SLE. Many of the SLE susceptibility genes have known immune functions and can be placed into several focal pathways. These pathways highlight the importance of immune complex clearance (complement and phagocytosis), lymphocyte signaling (T-and B-cell signaling) and the innate immune response (IFN and NF-kB signaling) in SLE predisposition. Current follow-up efforts are now focused on precisely identifying the causative genetic variants and their effects, and the biological mechanisms through which they predispose to SLE, which will provide a major advance in our ability to translate genetic associations into diagnostic applications. In addition, reduced DNA methylation, histone hypoacetylation and hyperacetylation and the overexpression of certain miRNAs, resulting in immune imbalance, have been shown to be associated with the onset and progression of SLE. Future work should determine how epigenomics connects the environment to cell biology and autoreactivity. Unlike genetic alterations, which are permanent, epigenetic alterations are reversible. This opens the possibility of introducing preventive measures and using epigenetic drugs to reverse the pattern of epigenetic alterations to relieve the phenotype. Moreover, the aberrant expressions and activity of TFs, altered transcript editing and dysfunctional PTMs also play important roles in the pathogenesis and development of SLE. On the other hand, the protein and metabolic profiles provide high sensitivity and specificity to predict the diagnosis of SLE. Continued work will be required to confirm the quantification of some interested biomarker candidates in a larger and different population of SLE patients. Overall, much remains to be done before the etiology of SLE and LN becomes fully understood.
